Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AZD 8931

Known as: AZD-8931, AZD8931 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Summary Background A substantial change in trial methodology for solid tumours has taken place, in response to increased… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
2016
2016
PurposeAZD8931 is an orally bioavailable, reversible tyrosine kinase inhibitor of EGFR, HER2, and HER3 signaling. The Phase II… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
2014
2014
Modest up-regulation of either HER-ligands or receptors has been implicated in acquired endocrine resistance. AZD8931, a dual… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2014
2014
Fibroblasts in the tumour stroma (cancer-associated fibroblasts) influence tumour progression and response to therapeutics… Expand
  • figure 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Review
2014
Review
2014
HER2 (human epidermal growth factor receptor 2)-targeted therapy in breast cancer is one of the earliest and arguably most… Expand
2014
2014
IntroductionEpidermal growth factor receptor (EGFR) overexpression has been associated with prognostic and predictive value in… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2013
2013
SummaryAim AZD8931 is an oral equipotent inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling. This Phase I, open… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
2013
2013
Deregulation of HER family signaling promotes proliferation and tumor cell survival and has been described in many human cancers… Expand
2013
2013
531 Background: Preclinical data suggest a key role for EGFR inhibition in delaying acquired resistance to ET in ER+ breast… Expand
Highly Cited
2010
Highly Cited
2010
Purpose: To test the hypothesis that simultaneous, equipotent inhibition of epidermal growth factor receptor (EGFR; erbB1), erbB2… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4